Intellia Therapeutics, Inc. (NTLA) vs TransMedics Group, Inc. (TMDX)
A side-by-side comparison of Intellia Therapeutics, Inc. and TransMedics Group, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 2, 2026. Differences are shown without an overall score or investment verdict.
NTLA
Intellia Therapeutics, Inc.
$12.29HealthcareDelayed quote: Oct 2, 2026, 3:55 PM EDT
TMDX
TransMedics Group, Inc.
$79.33HealthcareDelayed quote: Oct 2, 2026, 3:55 PM EDT
Total return — NTLA vs TMDX
growth of $100 · dividends reinvested · last 7yNTLA -16.2% (-2.5%/yr)TMDX +251.7% (+19.7%/yr)TMDX compounded faster over this window
NTLA TMDX
NTLA vs TMDX: by the numbers
- •TMDX is the larger company ($2.74B vs $1.72B market cap).
- •TMDX is profitable (22.69% net margin) while NTLA runs a net loss (-672.16%).
- •TMDX grew revenue faster over the past five years (86.12% vs 7.31% CAGR).
Metrics side by side
Valuation
| Metric | NTLA | TMDX |
|---|---|---|
| P/E ratio | N/A | 20.55 |
| Forward P/E | N/A | 54.08 |
| P/S ratio | 28.85 | 4.10 |
| P/B ratio | 2.36 | 5.29 |
| EV / EBITDA | N/A | 26.57 |
| FCF yield | N/A | 2.88% |
Profitability
| Metric | NTLA | TMDX |
|---|---|---|
| Gross margin | 76.47% | 58.69% |
| Operating margin | -651.67% | 12.21% |
| Net margin | -672.16% | 22.69% |
| ROE | -54.96% | 29.28% |
| ROIC | -54.45% | 5.87% |
Growth (annualized)
| Metric | NTLA | TMDX |
|---|---|---|
| Revenue CAGR (5Y) | 7.31% | 86.12% |
| Total return CAGR (5Y) | -38.17% | 19.20% |
Frequently asked
- Which has grown faster, NTLA or TMDX?
- Over the past five years, TMDX grew revenue faster — NTLA at a 7.31% CAGR versus TMDX at 86.12%.
- Is NTLA or TMDX more profitable?
- TMDX runs the higher net margin — NTLA at -672.16% versus TMDX at 22.69%.
- How have NTLA and TMDX total returns compared?
- Over the past 5 years, NTLA delivered -38.17% and TMDX delivered 19.20% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
TransMedics P/E ratioIntellia Therapeutics ROETransMedics ROEIntellia Therapeutics operating marginTransMedics operating marginIntellia Therapeutics revenue growthTransMedics revenue growthIntellia Therapeutics free cash flowTransMedics free cash flow
Intellia Therapeutics & TransMedics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 2, 2026.